BioCryst to Acquire Astria in $700M Deal
BioCryst Pharmaceuticals Inc. announced it will acquire Astria Therapeutics Inc. in a cash-and-stock transaction valued at approximately $700 million.
The acquisition strengthens BioCryst's foothold in the rare disease and immunology market, combining its commercialization capabilities with Astria's innovative research pipeline.
- Transaction value: approximately $700 million
- Payment terms: $8.55 in cash plus 0.59 BioCryst shares per Astria share
- Implied value: about $13 per share, a 53% premium over Astria's October 13 closing price
The biopharmaceutical power play signals a new era in therapies for hereditary angioedema (HAE) and allergic and immunologic disorders.
Author's summary: BioCryst acquires Astria for $700M.